Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says
Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. BIIB has been the subject of a number of other reports. StockNews.com downgraded shares […]
Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. BIIB has been the subject of a number of other reports. StockNews.com downgraded shares […]
